Head to Head Analysis: Ceapro (OTCMKTS:CRPOF) versus Lunai Bioworks (NASDAQ:LNAI)

Ceapro (OTCMKTS:CRPOF) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Insider & Institutional Ownership

71.4% of Lunai Bioworks shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Ceapro and Lunai Bioworks”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ceapro	$7.14 million	1.86	-$3.49 million	($0.06)	-2.83
Lunai Bioworks	N/A	N/A	-$178.01 million	($7.70)	-0.11

Ceapro has higher revenue and earnings than Lunai Bioworks. Ceapro is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ceapro has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Lunai Bioworks has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.

Profitability

This table compares Ceapro and Lunai Bioworks’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ceapro	-69.60%	-20.30%	-18.07%
Lunai Bioworks	N/A	-222.12%	-152.88%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ceapro and Lunai Bioworks, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ceapro	0	0	0	0	0.00
Lunai Bioworks	1	0	0	0	1.00

Summary

Ceapro beats Lunai Bioworks on 6 of the 11 factors compared between the two stocks.

About Ceapro

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

About Lunai Bioworks

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.